Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to treating severe autoimmune and neuromuscular diseases. The company's lead clinical candidate, claseprubart (DNTH103), is a monoclonal antibody engineered to selectively inhibit the active form of the C1s complement protein, targeting indications such as generalized myasthenia gravis (gMG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP). A second key pipeline asset, DNTH212, is a bifunctional fusion protein designed to inhibit BDCA2 and BAFF/APRIL pathways for conditions like Sjögren's disease and systemic lupus erythematosus. Dianthus differentiates itself by designing therapies with extended half-lives, enabling convenient, self-administered subcutaneous injections as infrequently as once every two to four weeks. Operating primarily out of New York and Massachusetts, the company went public in September 2023 through a reverse merger with Magenta Therapeutics.
